Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic Neuroendocrine Tumors

NCT02943733 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT02943733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02943733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic Neuroendocrine Tumors
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 1
Overall status
Terminated
Start date
August 22, 2017
Completion date
January 31, 2022
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, neoplasms, neuroendocrine tumors, tumors